Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials, validating biotech’s waning interest Read more

Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure Read more

Gilead cancels midstage HIV trial as FDA’s clinical hold remains intact Read more

Navid Gholampour

Navid has over a decade of experience in Life Sciences recruitment. He partners with leaders to build patient-focused and innovative organisation